See more : Glen Burnie Bancorp (GLBZ) Income Statement Analysis – Financial Results
Complete financial analysis of Delivra Health Brands Inc. (DHBUF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Delivra Health Brands Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shinpo Co., Ltd. (5903.T) Income Statement Analysis – Financial Results
- Norra Metals Corp. (NRRMF) Income Statement Analysis – Financial Results
- Caspar Asset Management S.A. (CSR.WA) Income Statement Analysis – Financial Results
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF) Income Statement Analysis – Financial Results
- Viking Therapeutics, Inc. (0VQA.L) Income Statement Analysis – Financial Results
Delivra Health Brands Inc. (DHBUF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://delivrahealthbrands.com
About Delivra Health Brands Inc.
Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. It is involved in selling of cannabis, liquid sleep shots, sleep powder packets, and pain relief creams. The company is headquartered in Vancouver, Canada.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.38M | 9.79M | 8.14M | 7.96M | 8.38M | 11.47M | 725.98K | 75.95K | 246.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 5.98M | 4.97M | 5.54M | 6.04M | 9.02M | 8.46M | -197.84K | -176.42K | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 6.40M | 4.82M | 2.60M | 1.92M | -631.00K | 3.01M | 923.82K | 252.37K | -951.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 51.70% | 49.26% | 31.99% | 24.12% | -7.53% | 26.24% | 127.25% | 332.29% | -385.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 352.00K | 72.00K | 179.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 4.25M | 4.08M | 4.89M | 7.89M | 14.20M | 18.23M | 10.67M | 7.03M | 46.25K | 45.97K | 36.51K | 39.67K | 45.88K | 32.86K | 54.67K |
Selling & Marketing | 1.55M | 775.00K | 1.60M | 1.01M | 2.22M | 2.91M | 780.04K | 470.61K | 30.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.80M | 4.86M | 6.50M | 8.89M | 16.42M | 21.14M | 11.45M | 7.50M | 46.25K | 45.97K | 36.51K | 39.67K | 45.88K | 32.86K | 54.67K |
Other Expenses | 1.31M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 7.11M | 6.19M | 8.62M | 11.18M | 19.09M | 21.74M | 11.52M | 8.60M | 46.25K | 45.97K | 36.51K | 39.67K | 45.88K | 32.86K | 54.67K |
Cost & Expenses | 13.09M | 11.15M | 14.15M | 17.22M | 28.11M | 30.20M | 11.32M | 8.42M | 46.25K | 45.97K | 36.51K | 39.67K | 45.88K | 32.86K | 54.67K |
Interest Income | 0.00 | 250.00K | 635.00K | 41.00K | 318.00K | 140.00K | 14.50K | 24.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 169.00K | 250.00K | 635.00K | 0.00 | 804.00K | 45.00K | 1.90M | 149.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.31M | 1.33M | 2.12M | 2.22M | 2.34M | 879.00K | 456.79K | 1.10M | 26.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | 2.35M | -33.00K | -4.26M | -7.04M | -54.86M | -25.33M | -10.13M | -7.19M | -2.73M | -45.97K | -36.51K | -39.67K | -45.88K | -32.86K | -54.67K |
EBITDA Ratio | 19.02% | -0.34% | -47.83% | 86.11% | -200.91% | -156.39% | -1,394.95% | -9,515.74% | -18.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -710.00K | -1.36M | -6.01M | -21.96M | -61.26M | -28.14M | -10.60M | -6.15M | -46.25K | -45.97K | -36.51K | -39.67K | -45.88K | -32.86K | -54.67K |
Operating Income Ratio | -5.74% | -13.92% | -73.87% | -276.01% | -730.70% | -245.41% | -1,459.87% | -8,093.49% | -18.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.59M | 1.18M | -599.00K | -15.63M | -1.50M | 73.00K | -2.01M | -2.29M | -512.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax | 876.00K | -184.00K | -7.01M | -22.67M | -62.77M | -27.97M | -12.61M | -8.44M | -46.25K | -45.97K | -36.51K | -39.67K | -45.88K | 0.00 | 0.00 |
Income Before Tax Ratio | 7.08% | -1.88% | -86.12% | -284.97% | -748.70% | -243.92% | -1,736.52% | -11,110.24% | -18.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 250.00K | 635.00K | 19.28M | 17.70M | -285.00K | 1.90M | 149.39K | -26.97K | 0.00 | 0.00 | 0.00 | 45.88K | 32.86K | 54.67K |
Net Income | 876.00K | -184.00K | -7.01M | -28.54M | -79.86M | -27.85M | -12.61M | -8.44M | -46.25K | -45.97K | -36.51K | -39.67K | -45.88K | -32.86K | -54.67K |
Net Income Ratio | 7.08% | -1.88% | -86.12% | -358.70% | -952.49% | -242.93% | -1,736.52% | -11,110.24% | -18.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | 0.00 | 0.00 | -0.03 | -0.13 | -0.37 | -0.15 | -0.11 | -0.16 | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.33 |
EPS Diluted | 0.00 | 0.00 | -0.03 | -0.13 | -0.37 | -0.15 | -0.11 | -0.16 | -0.02 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.33 |
Weighted Avg Shares Out | 285.71M | 252.62M | 252.62M | 225.96M | 214.64M | 179.77M | 120.06M | 53.80M | 2.29M | 1.75M | 1.73M | 1.91M | 2.29M | 2.14M | 168.21K |
Weighted Avg Shares Out (Dil) | 285.66M | 252.62M | 252.62M | 225.96M | 214.64M | 179.77M | 120.06M | 53.80M | 2.29M | 1.75M | 1.73M | 1.91M | 2.29M | 2.14M | 168.21K |
Delivra Health to launch Immunity Support Sleep Shots in Canada
Delivra Health to launch Immunity Support Sleep Shots in Canada
Delivra Health's Dream Water(R) Brand to Launch Its Immunity Support Sleep Shot in the Canadian Market
Delivra Health Brands Announces Adoption of a New Fixed Share Option Plan
Delivra Health Brands sees revenue jump in first half of fiscal 2024
Delivra Health and Its Brands LivRelief(TM) and Dream Water(R) Report Results for Second Quarter of Fiscal 2024
Delivra Health launches branded sleep gummies in Canada
Delivra Health Brands' Dream Water(R) Brand Launches its Sleep Gummies into the Canadian Market
Delivra Health Brands Announces Closing of Non-Brokered Private Placement of Units
Delivra Health Brands Announces Non-Brokered Private Placement of Units
Source: https://incomestatements.info
Category: Stock Reports